The only data in the literature addressing spliceosome patients is that they have the worst of the worst prognosis. So as you know, in relapsed refractory AML, the survival is unfortunately quite poor. Median survival in studies ranges from two to four months. And what we understand from the literature is that the lower end of that range is for the spliceosome patients. But as far as we know, nobody’s ever demonstrated you can get a response. So in FLT3, what we’re looking to do is can we improve upon FLT3 inhibitors as a class with our FLT3 IRAK4 targeting molecule, M of usurtive, and that would be beating a 12% CR rate or a 22.6% CR-CRH rate. And in spliceosome patients it would be anything that would be greater than 0. Presumably, something north of 10 would be very exciting in that setting.
Is that helpful?
Q – Unidentified Analyst: Okay. Yes. And I have another question for the triplet. Do you think you need to do more dose work for the combination? And also, do you anticipate any drug-drug interaction with a triplet regimen?
Jim Dentzer: Excellent question. So the answer to the second one of, do we expect any DDI, drug-drug interaction, I’d say we don’t expect it based on the work we’ve done in the lab and the clinical work we’ve done to-date, we don’t see that there’s an overlapping safety profile. That said, of course, that’s why you’re on the sites to see whether or not that stays consistent. In terms of our expectation, could you remind me where you were headed with that first part of the question in the triplet?
Unidentified Analyst: Do you need to do more dose work?
Jim Dentzer : That’s right. So the answer to that is yes. I mean, our first foray into the triplet study, we’re going to be evaluating both safety and efficacy. So we think we know the right dose. We certainly know the right dose for monotherapy. We think we have the right dose in combination with ibrutinib and venetoclax, but this will be the first time we’ve studied the triplet in the clinic of ASA and Ven and Ella. So I think based on the results of those, one of the things we’re going to want to see is, can we determine the appropriate dosing regimen for emavusertib in that setting. Any other questions Yale?
Unidentified Analyst: No, that’s great. Thank you.
Jim Dentzer : Excellent. Thank you.
Operator: Your next question comes from Dane Leone from Raymond James. Dane, please go ahead.
Jim Dentzer : Dane, look, not there.
Operator: He disconnected from the line. Your next question comes from A.J. Rashid [ph] from Columbia Eagle [ph]. A.J., please go ahead.
Unidentified Analyst : On the overland dispute.
Jim Dentzer : That last one broke up. I’m sorry about that. Are there any other questions in the queue?
Operator: Okay. It appears there are no further questions. So this concludes our question-and-answer session. I’d like to turn the conference back over to the company’s President and Chief Executive Officer, James Dentzer for any closing remarks.
Jim Dentzer : Thank you, Colin, and thank you, everyone, for joining today’s call. As always, thank you to the patients and families participating in our clinical trials to our team at Curis for their tireless commitment and to our partners at Origin and the NCI for their ongoing health and support. We look forward to updating you again soon. Colin?
Operator: Ladies and gentlemen, this concludes your conference call for today. We thank you for participating and ask that you please disconnect your lines.
